DRUGS & SUPPLEMENTS
Nifcard is aSelective calcium channel blocker class II, a derivative of dihydropyridine. This medication inhibits the entry of calcium into cardiomyocytes and vascular smooth muscle cells. Nifcard has antianginal and hypotensive action. This drug lowers the tone of vascular smooth muscle. Nifcard dilates coronary and peripheral arteries, lowers blood pressure and slightly - myocardial contractility, reduces afterload and myocardial oxygen demand. This medicine improves coronary blood flow. Nifcard practically does not possess antiarrhythmic activity, it does not inhibit the conductance of myocardium.
When administered orally Nifcard is rapidly absorbed from the gastrointestinal tract. This drug undergoes metabolism in the "first pass" through the liver. The protein binding is 92-98%. Nifcard metabolized in the liver to form inactive metabolites. T1/2 is about 2 hours. This medication excreted mainly by the kidneys as metabolites in trace amounts in unchanged form; 20% is excreted from the gut in the form of metabolites.
Why is Nifcard prescribed?
Prevention of angina attacks, in some cases - relief of angina attacks, hypertension, hypertensive crises, Raynaud's disease.
Dosage and administration
The dosing regimen is individual. For oral administration the initial dose is 10 mg 3-4 times / day. If necessary the dose gradually increased up to 20 mg 3-4 times / day. In some cases (variant angina, severe hypertension) for a short time the dose can be increased to 30 mg 3-4 times / day. For relief of hypertensive crisis, as well as angina attack this drug can be used sublingually in 10-20 mg (rarely 30 mg).
To IN relieve an angina attack or hypertensive crisis - 5 mg for 4-8 hours.
Intracoronary dose for relief of acute coronary artery spasm injected bolus is 100-200 mcg. With stenosis of major coronary vessels starting dose is 50-100 micrograms.
The maximum daily dose: oral - 120 mg, IV - 30 mg.
Nifcard side effects, adverse reactions
Cardiovascular: flushing of the skin, a feeling of warmth, tachycardia, hypotension, peripheral edema; rarely - bradycardia, ventricular tachycardia, asystole, increased angina attacks.
Digestive system: nausea, heartburn, diarrhea, rarely - liver function impairment and in rare cases - gingival hyperplasia. The chronic administration in high doses may cause dyspeptic symptoms, elevated liver enzymes, intrahepatic cholestasis.
CNS and peripheral nervous system: headache. The chronic administration in high doses may cause paresthesia, muscle pain, tremors, visual disturbances light, and sleep disorders.
Hemopoietic system: in rare cases - leukopenia, thrombocytopenia.
Urinary system: an increase in daily diuresis. The chronic administration in high doses may cause renal dysfunction.
Endocrine system: in rare cases - gynecomastia.
Allergic reactions: skin rash.
Local reactions: for IV injections might burning at the injection site.
Within 1 min after intracoronary administration it can be a result in the negative inotropic action of Nifcard, the increase in heart rate, hypotension, and these symptoms gradually disappear within 5-15 minutes.
Hypotension, collapse, cardiogenic shock, severe heart failure, severe aortic stenosis; increased sensitivity to Nifcard.
Using during pregnancy and breastfeeding
Adequate and well-controlled studies safety of Nifcard in pregnancy was not been conducted. The use of Nifcard in pregnancy is not recommended.
Because Nifcard is excreted in breast milk, you should avoid its use during lactation or to stop breastfeeding during the treatment with this medication.
In experimental studies it have been revealed embryotoxic, fetotoxic and teratogenic effects of Nifcard.
Category effects on the fetus by FDA - C.
In patients with stable angina at the beginning of treatment paradoxical enhancement anginalnyh pain may occurs, with pronounced coronary sclerosis and unstable angina - the aggravation of myocardial ischemia. Not recommended to use short-acting drugs for long-term treatment of angina or hypertension, because it is possible the development of unpredictable changes in BP and reflex angina.
Nifcard drug interactions
Nitrates, beta-blockers, diuretics, tricyclic antidepressants, fentanyl, alcohol increase the hypotensive effect of Nifcard Quality Pharmaceutical Laboratory. This medication increases the activity of theophylline reduces the renal clearance of digoxin. Nifcard increases the side effects of vincristine ; increases the bioavailability of cephalosporins (cefixime). Cimetidine and ranitidine increase the level of this drug in plasma. Diltiazem slows the metabolism (requires dose reduction of Nifcard) of Nifcard Quality Pharmaceutical Laboratory. This medicine is incompatible with rifampicin (accelerates biotransformation and does not allow to create effective concentration). Grapefruit juice (large quantity) increases its bioavailability.
Nifcard in case of emergency / overdose
Symptoms: sudden bradycardia, bradyarrhythmia, hypotension, in severe cases - collapse, slowing conduction. When you receive a large number of retard-tablets symptoms of intoxication occur no earlier than 3-4 h and may additionally be expressed in loss of consciousness up to coma, cardiogenic shock, convulsions, hyperglycemia, metabolic acidosis, hypoxia.
Treatment: gastric lavage, activated charcoal method, injections of norepinephrine, calcium chloride or calcium gluconate in a solution of atropine (IV). Hemodialysis is ineffective.
Nifcard pharmaceutical active ingredients containing related brand and generic drugs:
Active ingredient is the part of the drug or medicine which is biologically active. This portion of the drug is responsible for the main action of the drug which is intended to cure or reduce the symptom or disease. The other portions of the drug which are inactive are called excipients; there role is to act as vehicle or binder. In contrast to active ingredient, the inactive ingredient's role is not significant in the cure or treatment of the disease. There can be one or more active ingredients in a drug.
Nifcard available forms, composition, doses:
Form of the medicine is the form in which the medicine is marketed in the market, for example, a medicine X can be in the form of capsule or the form of chewable tablet or the form of tablet. Sometimes same medicine can be available as injection form. Each medicine cannot be in all forms but can be marketed in 1, 2, or 3 forms which the pharmaceutical company decided based on various background research results.
Composition is the list of ingredients which combinedly form a medicine. Both active ingredients and inactive ingredients form the composition. The active ingredient gives the desired therapeutic effect whereas the inactive ingredient helps in making the medicine stable.
Doses are various strengths of the medicine like 10mg, 20mg, 30mg and so on. Each medicine comes in various doses which is decided by the manufacturer, that is, pharmaceutical company. The dose is decided on the severity of the symptom or disease.
Nifcard destination | category:
Destination is defined as the organism to which the drug or medicine is targeted. For most of the drugs what we discuss, human is the drug destination.
Drug category can be defined as major classification of the drug. For example, an antihistaminic or an antipyretic or anti anginal or pain killer, anti-inflammatory or so.
Nifcard Anatomical Therapeutic Chemical codes:
A medicine is classified depending on the organ or system it acts [Anatomical], based on what result it gives on what disease, symptom [Therapeutical], based on chemical composition [Chemical]. It is called as ATC code. The code is based on Active ingredients of the medicine. A medicine can have different codes as sometimes it acts on different organs for different indications. Same way, different brands with same active ingredients and same indications can have same ATC code.
Nifcard pharmaceutical companies:
Pharmaceutical companies are drug manufacturing companies that help in complete development of the drug from the background research to formation, clinical trials, release of the drug into the market and marketing of the drug.
Researchers are the persons who are responsible for the scientific research and is responsible for all the background clinical trials that resulted in the development of the drug.
Frequently asked QuestionsCan i drive or operate heavy machine after consuming Nifcard?
Depending on the reaction of the Nifcard after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Nifcard not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.Is Nifcard addictive or habit forming?
Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
ReviewsDrugs.com conducted a study on Nifcard, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Nifcard consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.
The information was verified by Dr. Arunabha Ray, MD Pharmacology